The study objective was to evaluate the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment.
| INTRODUCTION
Vilaprisan is a highly potent selective progesterone receptor modulator under investigation for the treatment of symptomatic uterine fibroids (UF) and endometriosis. UF (leiomyomas or myomas) are the most common benign smooth muscle tumours of the myometrium and are clinically relevant in up to 40% of premenopausal women aged 35-40 years. 1 Symptoms include heavy menstrual bleeding, which can lead to anaemia, fatigue, painful periods, abdominal protuberance, painful intercourse or pelvic pressure, and bladder or bowel dysfunction. UF have also been linked with reproductive issues that can negatively impact on fertility and pregnancy. 2, 3 In 2 phase 2 clinical studies in women with UF, treatment with vilaprisan resulted in effective bleeding control and reductions in fibroid volume, and demonstrated a favourable safety profile. 4, 5 Based on these promising results, vilaprisan is currently being investigated in phase 3 studies in patients for long-term treatment of UF. 6 Previous clinical drug-drug interaction studies with the potent cytochrome P450 3A4 (CYP3A4) inhibitor itraconazole and the potent CYP3A4 inducer rifampicin showed a mean increase by 6.2-fold and a reduction by 96% of the vilaprisan exposure, respectively, confirming preclinical investigations that vilaprisan is extensively metabolised by CYP3A4. 7, 8 Biotransformation occurs mainly by oxidation reactions at the steroid skeleton, as well as reductions of the 3-keto group, leading to a complex metabolite pattern with rather low exposure (<10%)
to single metabolites in plasma. The 2 main metabolites elicit only marginal pharmacological activity at the progesterone receptor, not contributing to clinical efficacy. Vilaprisan is highly bound to plasma proteins with an unbound fraction of 5.29%. Furthermore, based on a physiologically based pharmacokinetic model, the estimated fraction metabolised by CYP3A4 was >0.9 for vilaprisan. 8, 9 The fraction escaping first-pass metabolism in the gut (F G ) was estimated to be about 0.65 and the hepatic bioavailability was~0.93 (F H ), consistent with an oral bioavailability of 61%. 7 Clinical results from an intravenous microtracer study showed that vilaprisan is extensively distributed into tissues, as reflected by a large volume of distribution at steady state of~360 L, and has a moderate plasma clearance of~7 L/h with negligible contribution of renal clearance to total elimination. The terminal plasma elimination half-life of~40 hours is similar after intravenous and oral administration. 7 In vitro interaction studies suggested no clinically relevant interaction of vilaprisan with the main CYP enzymes or transporters (i.e. as a perpetrator). The metabolic activity of CYP3A4 may be lower in patients with mild or moderate hepatic impairment than in patients with normal hepatic function, which could potentially result in decreased clearance and therefore higher systemic exposure. [10] [11] [12] Hence, the pharmacokinetics of vilaprisan may be altered in patients with reduced liver function. It is anticipated that vilaprisan could be used for patients with comorbidities, including those with mild or moderate hepatic impairment. Therefore, it is important to gain a clear understanding of the impact of hepatic impairment on the pharmacokinetics of vilaprisan, to guide labelling and dosing recommendations for this subgroup of the target patient population. An overview of the study design is shown in Figure 1 .
All local legal and regulatory requirements were met and the study was conducted in accordance with the ethical principles of the Decla- 
| Participants
Although the target population for vilaprisan is women with UF or endometriosis, the study was conducted in both male and female participants, as physiological differences between male and female participants were not expected to influence the main study outcomes.
Three parallel treatment groups were included: participants with either (i) mild (CP-A) or (ii) moderate (CP-B) hepatic impairment ( 
| Assessment and variables
Plasma (blood samples taken 1.0 hour pre-vilaprisan dosing and at 0.5, Vilaprisan was determined in individual urine and plasma samples using a 150 × 4.6 mm Prodigy ODS3, 5-μm analytical column (Phenomenex, 00F-4097-E0) following elution with an acetonitrile/ ammonium acetate buffer gradient system. All methods were validated according to the relevant European and US guidelines.
14,15
The fraction of unbound (f u ) vilaprisan was determined at 2, 24, and 48 hours post-dosing in plasma ex vivo using the Transil method. 16 Transil is a widely used rapid dialysis method using immobilised plasma proteins on membrane beads. Plasma samples were spiked with carbon 14-labelled vilaprisan at a nominal concentration
, enabling reliable detection of vilaprisan in plasma. Participants with impaired hepatic function were hospitalized for two days after treatment, controls for one day after treatment Clinical laboratory tests were performed 1 day pre-vilaprisan dosing, and 1, 3 and 13 days postdosing.
| Statistics
All participants treated with vilaprisan were included in the pharmacokinetic analyses. Analyses of variance (ANOVAs), including fixed hepatic group effects, were used for the comparison of the pharmacokinetic parameters AUC u and C max,u between study groups. Logtransformed parameter values were used, as the parameters were assumed to be log-normally distributed. The point estimates and 90% confidence intervals (CIs) of the ratios of the groups were derived by retransforming the point estimates (least squares means) and the 90% CIs of the corresponding models to the original scale. No formal statistical sample size estimation had been performed for this study due to the exploratory character of the study. Sample size was based on recommendations from the Food and Drug Administration Guidance for Industry on hepatic impairment studies. 17 Based on experience in previous pharmacokinetic studies with vilaprisan at Bayer, the chosen sample size of n = 36 subjects, i.e. 9 subjects with mild (CP-A) hepatic impairment, 9 subjects with moderate (CP-B)
hepatic impairment, and 18 sex-, age-and weight-matched subjects, was considered to be sufficient to detect a moderate, at least 2-fold increase in AUC.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 18 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/2018. Baseline characteristics for all treated participants (n = 36) are summarised in Table 2 ).
In line with the matching of control participants, sex, age and body weight were similar across cohorts. There were 5 and 4 participants with Child-Pugh score 5 or 6, respectively, in the mild hepatic impairment group, and 5, 1 and 3 participants with Child-Pugh score of 7, 8 or 9, respectively, in the moderate hepatic impairment group.
The study selection criteria excluded participants using CYP3A4 or P-glycoprotein inhibitors. Based on the current knowledge of the pharmacokinetic and metabolic characteristics of vilaprisan, none of the concomitant medications received by any of the study participants was expected to have any interaction with vilaprisan, and thereby influence interpretation of the data. A table with the concomitant medication administered is provided in the Supporting Information.
| Pharmacokinetic results
All pharmacokinetic data are discussed with reference to the geometric mean. Following single oral dose administration of vilaprisan 2 mg, geometric mean maximum concentrations were observed at 2.5, 2.0, 1.5 and 2.0 hours postadministration in the matched control cohorts for mild and moderate hepatic impairment, mild hepatic impairment and moderate hepatic impairment cohorts, respectively ( Figure 3A) .
Thereafter, plasma concentrations declined in a biphasic pattern in all 4 cohorts, with an initial rapid distribution phase followed by a Child-Pugh score, n 
| Protein binding
Impaired hepatocyte function in patients with hepatic impairment could lead to decreased synthesis and dysfunction of albumin, resulting in decreased plasma protein binding and altered drug disposition. 20 As vilaprisan binds primarily to albumin, plasma protein AUC, area under the concentration vs time curve; AUC u , area under the concentration vs time curve in plasma from zero to infinity for unbound drug; CI, confidence interval; CL/F, total apparent oral vilaprisan clearance; CL u /F, unbound oral vilaprisan clearance; CL R , renal clearance from plasma; C max , maximum observed drug concentration; C max,u , maximum observed unbound drug concentration; CV, coefficient of variation; LS, least-square; t max , time to reach C max ; t 1/2 , terminal half-life; V z /F, apparent volume of distribution during the terminal phase; V z,u /F, apparent volume of distribution during the terminal phase for unbound drug.
a Median values (range).
in the control mild hepatic impairment, control moderate hepatic impairment, mild hepatic impairment, and moderate hepatic impairment cohorts, respectively. The C max,u was approximately equal for the participants with hepatic impairment and the control cohorts, with a moderate degree of variability in measurements ranging from 26.7-43.4% coefficient of variation (Table 3) .
| Relationship between pharmacokinetic parameters and hepatic function parameters
The exploratory relationships between the primary pharmacokinetic parameters AUC u and C max,u and the baseline hepatic function param- 
| Relationship between pharmacokinetic parameters and Child-Pugh scores
The relationships between the pharmacokinetic parameters for vilaprisan and the individual Child-Pugh scores for the hepatic impaired participants were explored by plotting the C max,u and AUC u of vilaprisan as a function of Child-Pugh scores ( Figure 5 ). For C max,u no correlation was observed. For AUC u, the subjects with a
Child-Pugh score of 6 and 9 had the highest geometric mean exposure compared with subjects with Child-Pugh scores of 5, 7 and 8, indicating no clear correlation.
| Safety
All 36 The pharmacokinetic profile of vilaprisan in the control groups was very similar to that observed in previous studies conducted in postmenopausal women. 20 Furthermore, as expected, no relevant differences in the pharmacokinetics were seen between male and female subjects. Although vilaprisan is intended to be used for long-term treatment, investigating a single dose of 2 mg in this study was justified considering that vilaprisan shows linear pharmacokinetics upon multiple dosing, thereby allowing us to extrapolate these results to a multiple dosing scenario. 22 The expected vilaprisan exposure at steady state for participants with moderate hepatic impairment, given the anticipated accumulation due to the apparent slight prolongation of the terminal elimination half-life, is within the ranges included in a previous multiple-dose study. 22 In this previously conducted study, no safety concerns were identified with vilaprisan at doses up to 30 mg day −1 over 28 days. In this study, a single oral dose of vilaprisan 2 mg was well tolerated by participants of both sexes with mild or moderate hepatic impairment, and in participants with normal hepatic function. Safety findings in this study were comparable with observations from previous phase 1 and phase 2 studies in which vilaprisan was well tolerated, with no drug-related serious AEs even at the maximal daily doses used in females. 4, 5, 7, 21, 23 Here, the most frequently observed TEAEs were headache and nausea, which were also among the most common drug-related AEs reported alongside ovarian and cervical cyst (identified at ultrasound), fatigue, abdominal or pelvic pain, other gastrointestinal disorders (flatulence, constipation), hot flushes, and dizziness in previous studies. 4, 5, 7, 21, 23 A limitation of this study, which is inherent in the primary objective to investigate the pharmacokinetics of vilaprisan, is that safety data were only collected in a small participant population and after single oral dosing (n = 36). Nevertheless, the observed favourable safety pro- 
